Delcath Systems Quote - DCTH

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

11.94

Bid

9.90

Ask

14.88

Volume

191

0.00 Day's Range 0.00

3.12 52 Week Range 13.3011

Market Cap

381.767M

Previous Close

11.94

Open

Last Trade

11.58

Last Trade Time

03:04:16

Financial Volume

VWAP

Average Volume (3m)

374,258

Shares Outstanding

31,973,784

Dividend Yield

PE Ratio

-8.01

Earnings Per Share (EPS)

-1.49

Revenue

2.07M

Net Profit

-47.68M

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product candidate, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System, or Melphalan/HDS, is designed to administer high-dose chemotherapy... Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product candidate, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System, or Melphalan/HDS, is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Show more

Sector

Surgical,med Instr,apparatus

Industry

Surgical,med Instr,apparatus

Website

www.delcath.com

Headquarters

Wilmington, Delaware, USA

Founded

Delcath Systems Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker DCTH. The last closing price for Delcath Systems was US$11.94. Over the last year, Delcath Systems shares have traded in a share price range of US$ 3.12 to US$ 13.3011.

Delcath Systems currently has 31,973,784 shares outstanding. The market capitalization of Delcath Systems is US$381.77 million. Delcath Systems has a price to earnings ratio (PE ratio) of -8.01.

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the U.S. Food and Drug...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.21	1.79028132992	11.73	13.3011	11.475	411295	12.09562378	CS
4	2.065	20.9113924051	9.875	13.3011	9.33	371096	11.38618601	CS
12	2.96	32.9621380846	8.98	13.3011	8.08	374258	10.47384491	CS
26	4.17	53.667953668	7.77	13.3011	7.1701	323595	9.71016062	CS
52	8.75	274.294670846	3.19	13.3011	3.12	289972	7.71553335	CS
156	4.08	51.9083969466	7.86	13.3011	2.25	328791	5.92613185	CS
260	11.8401	11851.951952	0.0999	25.18	0.0999	247937	6.97126037	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
PRZOParaZero Technologies Ltd	US$ 2.65 (73.20%)	6.12M
VSTEVast Renewable Ltd	US$ 2.22 (70.77%)	10M
NUKKNukkleus Inc	US$ 18.07 (52.10%)	1.55M
YIBOPlanet Image International Ltd	US$ 5.70 (40.74%)	2
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.4479 (34.14%)	14.02M
DHAIDIH Holdings US Inc	US$ 0.90 (-34.78%)	1
PTPIPetros Pharmaceuticals Inc	US$ 0.3501 (-29.98%)	716.55k
NIVFNewGenIvf Group Ltd	US$ 0.30 (-29.20%)	116.68k
FTELFitell Corporation	US$ 27.84 (-27.48%)	100
LFLYLeafly Holdings Inc	US$ 1.00 (-22.48%)	1
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.4479 (34.14%)	14.02M
CEROCERo Therapeutics Holdings Inc	US$ 0.0749 (22.59%)	13.55M
VSTEVast Renewable Ltd	US$ 2.22 (70.77%)	10M
PRZOParaZero Technologies Ltd	US$ 2.65 (73.20%)	6.12M
RGTIRigetti Computing Inc	US$ 11.63 (4.49%)	5.08M